HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
|Articles|July 22, 2021
Pharmacy Clinical Pearl of the Day: Metformin and Kidney Function in Diabetes
Author(s)Saro Arakelians, PharmD
How should pharmacists manage a patient with diabetes on metformin with GFR below 30?
Advertisement
Clinical Pearl of the Day:
If a patient has diabetes, with metformin onboard as a treatment option, and GFR (kidney function) is below <30, metformin should be discontinued.
Explanation:
- Do not use metformin among patients with an eGFR less than 30.
- Do not start metformin among patients with an eGFR between 30 and 45.
- Stop metformin if a patient’s eGFR drops less than at any point during therapy.
- Complete a risk-benefit analysis of metformin if a patient’s eGFR drops to less than 45.
- Because metformin is renally cleared, it may cause some concern about nephrotoxicity, especially lactic acidosis, in patients with impaired renal function.
Reference:
Advertisement
Related to this article
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
2
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
3
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
4
New Data Reshapes Nonstatin Lipid Therapy Choices
5